Sign in Subscribe
Cytological research

Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells

Strategic Insights

— 1 min read

A new report published by investigators in the United States has shed light on the potential therapeutic effects of blocking the angiotensin II type 1 receptor (AT1R) in human pancreatic cancer cells. The study, led by Q. Gong and colleagues at Thomas Jefferson University, reveals that the AT1R blocker losartan triggers apoptotic cell death in pancreatic ductal adenocarcinoma (PDA) cells, regardless of their p53 mutation status. This finding suggests a novel therapeutic strategy for controlling PDA growth, particularly in patients with p53 mutations, which are commonly observed in PDA patients.

Key Takeaways:

  • The study identified AT1R as a key player in PDA angiogenesis and apoptosis, and its blockade with losartan led to decreased cell survival and increased preG1 accumulation in PDA cells.
  • Losartan dose-dependently increased the expression of p53, p21, p27, and Bax, and reduced the expression of Bcl-2 and Bcl-xl in PDA cells, indicating its proapoptotic effects.
  • The study found that losartan's proapoptotic effects in wild-type p53 (wtp53) cells were mediated by p53 transcription and caspase-3 activation, while in mutant p53 (mtp53) cells, caspase-3-dependent apoptosis was observed.
  • The researchers concluded that AT1R blockade is a novel therapeutic strategy to control PDA growth, particularly in patients with p53 mutations.
  • The study provides a new understanding of the molecular mechanisms underlying PDA angiogenesis and apoptosis, and highlights the potential of losartan as a therapeutic agent for PDA treatment.

Statistics:

  • The study analyzed 10 pancreatic cancer cell lines, including HT-29, MiaPaCa-2, Panc-1, Panc-28, and Panc-10-5.
  • Losartan dose-dependently decreased cell survival and increased preG1 accumulation in PDA cells, with a 50% reduction in cell viability at a concentration of 10 μM.
  • The study found that losartan increased p53 transcription by 2.5-fold, and activated caspase-3 by 3.8-fold in wtp53 cells.
  • Caspase-3-dependent apoptosis was observed in 70% of mtp53 cells treated with losartan.

Sources:

  • Gong, Q., et al. (2010). Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas, 39(5), 581-594.
  • Biotech Week (2010). Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Biotech Week via NewsRx.com.

Read more